title: Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
abstract: Drugs that covalently bond to their biological targets have a long history in drug discovery. A look at drug approvals in recent years suggests that covalent drugs will continue to make impacts on human health for years to come. Although fraught with concerns about toxicity, the high potencies and prolonged effects achievable with covalent drugs may result in less-frequent drug dosing and in wide therapeutic margins for patients. Covalent inhibition can also dissociate drug pharmacodynamics (PD) from pharmacokinetics (PK), which can result in desired drug efficacy for inhibitors that have short systemic exposure. Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncology and infectious disease.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN 46285, USA. Electronic address: rbauer@lilly.com.
authors.forename: Renato A
authors.initials: RA
authors.lastname: Bauer
mesh_terms: D017277:Drug Approval; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods*; D004351:Drug Resistance; D006801:Humans; D058990:Molecular Targeted Therapy; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010599:Pharmacokinetics
chemical_list: D004364:Pharmaceutical Preparations